Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: Respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway

Human Gene Therapy

Volumn 16, Issue 10, 2005, Pages 1157-1167

  Li, Hong ^a,b,g   Soria, Claudine ^b,c,d   Griscelli, Frank ^a   Opolon, Paule ^a   Soria, Jeannette ^e   Yeh, Patrice ^a   Legrand, Chantal ^c,d   Vannier, Jean Pierre ^b   Belin, Dominique ^f   Perricaudet, Michel ^a   Lu, He ^c,d,g  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^e HÔTEL DIEU   (France)

^f UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^g INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; UROKINASE; UROKINASE RECEPTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN DEGRADATION; RETROVIRUS; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENOVIRIDAE; MURINAE;

EID: 26644467462     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.1157     Document Type: Article

References (46)

1. APPELLA, E., ROBINSON, E.A., ULLRICH, S.J., STOPPELLI, M.P., CORTI, A., CASSANI, G., and BLASI, F. (1987). The receptor binding sequence of urokinase: A biological function for the growth factor module of proteases. J. Biol. Chem. 262, 4437-4440.
2. BACHARACH, E., ITIN, A., and KESHET, E. (1992). In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 89, 10686-10690.
3. BDEIR, K., KUO, A., SACHAIS, B.S., RUX, A.H., BDEIR, Y., MAZAR, A., HIGAZI, A.A.-R., and CINES, D.B. (2003). The kringle stabilizes urokinase binding to the urokinase receptor. Blood 102, 3600-3608.
4. BELIN, D., VASSALLI, J.D., COMBEPINE, C., GODEAU, F., NAGAMINE, Y., REICH, E., KOCHER, H.P., and DUVOISIN, R.M. (1985). Cloning, nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator. Eur. J. Biochem. 148, 225-232.
5. BLASI, F., and CARMELIET, P. (2002). uPAR: A versatile signalling orchestraler. Nat. Rev. Mol. Cell. Biol. 3, 932-943.
6. CARMELIET, P., MOONS, L., LIJNEN, R., BAES, M., LEMAITRE, V., TIPPING, P., DREW, A., EECKHOUT, Y., SHAPIRO, S., LIPU, F., and COLLEN, D. (1997). Urokinase-generated plasmin activates matrix metalloproteinase during aneurysm formation. Nat. Genet. 17, 439-444.
7. CROWLEY, C.W., COHEN, R.L., LUCAS, B.K., LIU, G., SHUMAN, M.A., and LEVINSON, A.D. (1993). Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. U.S.A. 90, 5021-5025.
8. DEMEULE, M., BERTRAND, Y., MICHAUD-LEVESQUE, J., JODOIN, J., ROLLAND, Y., and GABATHULER, R. (2003). Regulation of plasminogen activation: A role for melanotransferrin (p97) in cell migration. Blood 102, 1723-1731.
9. ELLIS, V., BEHRENDT, N., and DANO, K. (1991). Plasminogen activation by receptor-bound urokinase, a kinetic study with cell-associated and isolated receptor. J. Biol. Chem. 266, 12752-12758.
10. ESTREICHER, A., MUHLHAUSER, J., CARPENTIER, J.L., ORCI, L., and VASSALLI, J.D. (1990). The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell Biol. 111, 783-792.
11. FOEKENS, J.A., LOOK, M.P., PETERS, H.A., VAN PUTTEN, W.L., PORTENGEN, H., and KLIJN, J.G. (1995). Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer. J. Natl. Cancer Inst. 87, 751-756.
12. HE, C., WILHELM, S.M., PENTLAND, A.P., MARMER, B.L., GRANT, G.A., EISEN, A.Z., and GOLDBERG, G.I. (1989). Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc. Natl. Acad. Sci. U.S.A. 86, 2632-2636.
13. KIM, K.S., HONG, Y.-K., JOE, Y.-A., LEE, Y., SHIN, J.-Y., PARK, H.-E., LEE, I.-H., LEE, S.-Y., KANG, D.-K., CHANG, S.-I., and CHUNG, S.-I. (2003a). Anti-angiogenic activity of recombinant kringle domain of urokinase and its specific entry into endothelial cells. J. Biol. Chem. 278, 11449-11456.
14. KIM, K.S., HONG, Y.-K., LEE, Y., SHIN, J.-Y., CHANG, S.-I., CHUNG, S.-I., and JOE, Y.-A. (2003b). Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: Amino-terminal fragment and kringle domain. Exp. Mol. Med. 35, 578-585.
15. KOBAYASHI, H., MONIWA, N., SUGIMURA, M., SHINOHARA, H., OHI, H., and TERAO, T. (1993). Increased cell-surface urokinase in advanced ovarian cancer. Jpn. J. Cancer Res. 84, 633-640.
16. KOBAYASHI, H., GOTOH, J., FUJIE, M., SHINOHARA, H., MONIWA, N., and TERAO, T. (1994). Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within the growth factor-like domain of urokinase in an experimental and spontaneous metastasis model. Int. J. Cancer 57, 727-733.
17. KOOLWIJK, P., VAN ERCK, M.G., DE VREE, W.J., WEICH, H.A., HANEMAAIJER, R., and VAN HINSBERG, V.W. (1996). Cooperative effect of TNFα, bFGF and VEGF on the formation of tubular structure of human microvasculature endothelial cells in a fibrin matrix: Role of urokinase activity. J. Cell Biol. 132, 1177-1188.
18. LEFESVRE, P., ATTEMA, J., and VAN BEKKUM, D. (2002). Adenoviral gene transfer of antagonistic ATF-BPTI inhibits tumor growth. BMC Cancer 2, 17-31.
19. LE GAT, L., GOGAT, K., BOUQUET C., SAINT-GENIEZ, M., DARLAND D., VAN DEN BERGHE, L., MARCHANT, D., PROVOST, A., PERRICAUDET, M., MENASCHE, M., and ABITBOL, M. (2003). In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy. Gene Ther. 10, 2098-2103.
20. LI, H., LU, H., GRISCELLI, F., OPOLON, P., SUN, L.-Q., RAGOT, T., LEGRAND, Y., BELIN, D., SORIA, J., SORIA, C., PERRICAUDET, M., and YEH, P. (1998). Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependant tumor growth and dissemination in mice. Gene Ther. 5, 1105-1113.
21. LI, H., GRISCELLI, F., LINDENMEYER, F., OPOLON, P., SUN, L.-Q., CONNAULT, E., SORIA, J., SORIA, C., PERRICAUDET, M., YEH, P., and LU, H. (1999). Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice. Hum. Gene Ther. 10, 3045-3053.
22. LU, H., YEH, P., GUITTON, J.D., MABILAT, C., DESANLIS, F., MAURY, I., LEGRAND, Y., SORIA, J., and SORIA, C. (1994) Blockage of the urokinase receptor on the cell surface: Construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin. FEBS Lett. 356, 56-59.
23. LU, H., MABILAT, C., YEH, P., GUITTON, J.D., LI, H., POUCHELET, M., SHOEVAERT, D., LEGRAND, Y., SORIA, J., and SORIA, C. (1996). Blockage of urokinase receptor reduces in vitro the motility and deformability of endothelial cells. FEBS Lett. 380, 21-24.
24. MAGDOLEN, V., RETTENBERGER, P., KOPPITZ, M., GORETZKI, L., KESSLER, H., WEIDLE, U.H., KÖNIG, B., GRAEFF, H., SCHMITT, M., and WILHELM, O. (1996). Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur. J. Biochem. 237, 743-751.
25. MAZZIERI, R., MASIERO, L., ZANETTA, L., MONEA, S., ONISTO, M., GARBISA, S., and MIGNATTI, P. (1997). Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants. EMBO. J, 16, 2319-2332.
26. MIGNATTI, P.R.M., and RIFKIN, D.B. (1993). Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73, 161-195.
27. MIN, H.Y., DOYLE, L.V., VITT, C.R., ZANDONELLA, C.L., STRATTON-TOMAS, J.R., SHUMAN, M.A., and ROSENBERG, S. (1996). Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngenic mice. Cancer Res. 56, 2428-2433.
28. MUKHINA, S., STEPANOVA, V., TRAKTOUEV, D., POLIAKOV, A., BEABEALASHVILLY, R., GURSKY, Y., MINASHKIN, M., SHEVELEV, A., and TKACHUK, V. (2000). The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain: Characterization of interactions and contribution to chemotaxis. J. Biol. Chem. 275, 16450-16458.
29. NALDINI, L., TAMAGNONE, L., VIGNA, E., SACHS, M., HARTMANN, G., BIRCHMEIER, W., DAIKUHARA, Y., TSUBOUCHI, H.F.B., and COMOGLIO, P.M. (1992). Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 11, 4825-4833.
30. PARK, I.K., KIM, B.J., GOH, Y.J., LYU, M.A., PARK, C.G., HWANG, E.S., and KOOK, Y.H. (1997). Co-expression of urokinase-type plasminogen activator and its receptor in human gastric-cancer cell lines correlates with their invasiveness and tumorigenicity. Int. J. Cancer 71, 867-873.
31. QUAX, P.H., GRIMBERGEN, J.M., LANSINK, M., BARKER, A.H., BLATTER, M.C., BELIN, D., VAN HINSBERGH, V.W., and VERHEIJEN, J.H. (1998). Binding of human urokinase-type plasminogen activator to its receptor: Residues involved in species specificity and binding. Arterioscler. Thromb. Vasc. Biol. 18, 693-701.
32. PEPPER, M.S., SAPPINO, A.P., STOCKLIN, R., MONTESANO, R., ORCI, L., and VASSALLI, J.D. (1993). Upregulation of urokinase receptor expression on migrating endothelial cells. J. Cell Biol. 122, 673-684.
33. PLOUET, J., MORO, F., BERTAGNOLLI, S., COLDEBOEUF, N., MAZARGUIL, H., CLAMENS, S., and BAYARD, F. (1997). Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J. Biol. Chem. 272, 13390-13396.
34. PLOUG, M., RONNE, E., BEHRENDT, N., JENSEN, A.L., BLASI, F., and DANO, K. (1991). Cellular receptor for urokinase plasminogen activator: Carboxyl-terminal processing and membrane anchoring by glycosyl- phosphatidylinositol. J. Biol. Chem. 266, 1926-1933.
35. 2 as well as by the urokinase receptor regulates cell adhesion and migration. Blood 101, 1582-1590.
36. 2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J. Biol. Chem. 279, 18063-18072.
37. PYKE, C., KRISTENSEN, P., RALFKIAER, E., GRONDHAL-HANSEN, J., ERIKSEN, J., BLASI, F., and DANO, K. (1991). Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol. 138, 1059-1067.
38. REUNING, U., SPERL, S., KOPITZ, C., KESSLER, H., KRUGER, A., SCHMITT, M., and MAGDOLEN, V. (2003). Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr. Pharm. Des. 9, 1529-1543.
39. RIFKIN, D., MOSCATELLI, D., BIZIK, J., QUARTO, N., BLEI, F., DENNIS, P., FLAUMENHAFT, R., and MIGNATTI, P. (1990). Growth factor control of extracellular proteolysis. Cell Differ. Dev. 32, 313-318.
40. SAPPINO, A.P., BUSSO, N., BELIN, D., and VASSALLI, J.D. (1987). Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res. 47, 4043-4046.
41. SCHMITT, M., JANICKE, F., and GRAEFF, H. (1992). Tumor-associated proteases. Fibrinolysis 6, 3-26.
42. STEPHENS, R.W., PÖLLÄNEN, J., TAPIOVAARA, H., LEUNG, K.C., SIM, P.S., SALONEN, E.M., RONNE, E., BEHRENDT, N., DANO, K., and VAHERI, A. (1989). Activation of prourokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants. J. Cell Biol. 108, 1987-1995.
43. STRATFORD-PERRICAUDET, L.D., MAKEH, I., PERRICAUDET, M., and BRIAND, P. (1992). Widespread long-term gene transfer to mouse skeletal muscles and heart via an adenovirus vector. J. Clin. Invest. 90, 626-630.
44. STRATTON-THOMAS, J.R., DRUMMOND, R.J., FORREST, L.D., and ROSENBERG, S. (1997). Structure function studies of the urokinase receptor:urokinase system: Murine-human hybrid proteins define critical regions for species specificity. Fibrinolysis Proteolysis 11(Suppl. 3), 48-53.
45. WALTZ, D.A., NATKIN, L.R., FUJITA, R.M., WEI, Y., and CHAPMAN, H.A. (1997). Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 100, 58-67.
46. YAMAMOTO, M., SAWAYA, R., MOHANAM, S., BINDAL, A.K., BRUNER, J.M., OKA, K., RAO, V.H., TOMONAGA, M., NICOLSON, G.L., and RAO, J.S. (1994). Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res. 54, 3656-3661.